Archynetys Live news trend intelligence
◼ Archived Health 🔮 Archynetys predicts: fades by tomorrow — graded ✓ correct

Japanese drugmaker Takeda's Qdenga becomes first dengue vaccine approved in India

Takeda's Qdenga has become the first dengue vaccine approved for use in India, targeting one of the world's most at-risk populations.

7sources
8articles
5velocity
+0%since first seen
45d agofirst detected

Evidence dossier

Intelligence passport

66/100 Strong
7distinct sources shown
40velocity measurements
1language editions checked
All brief claims passed the second-source checkbrief evidence status

Measured timeline

  1. Detected The first matching coverage entered the Archynetys cluster.
  2. Latest coverage observed Most recent article currently attached to this story cluster.
  3. Peak measured velocity The recorded velocity reached 5.
  4. Evidence threshold reached The story had enough independent coverage for an explanatory brief.
  5. Outcome review added Archynetys revisited the signal after coverage cooled.

Source diversity sample: Taiwan News · Medical Xpress · The Times of India · NDTV · The Hindu · The Indian Express · Reuters.

How this dossier is built: methodology · AI policy · corrections.

📍 The outcome

India approved Takeda's Qdenga as the country's first dengue vaccine. The DCGI cleared the vaccine for individuals aged 4 to 60 years.

Epilogue added 43d ago, after coverage quieted.

Answered

Who is eligible for the Qdenga vaccine in India?

The vaccine is approved for individuals aged 4 to 60 years.

Which company developed the vaccine?

The vaccine was developed by the Japanese drugmaker Takeda.

Is this the first dengue vaccine approved in India?

Yes, Qdenga is India's first approved dengue vaccine.

Where it stands

India's Drug Controller General of India (DCGI) has cleared Takeda's Qdenga for use. The vaccine is approved for individuals between the ages of 4 and 60 years.

Coverage from Reuters, The Hindu, The Indian Express, and NDTV emphasizes the vaccine's role as the first of its kind in the country. The Times of India reports on the challenges of immunity regarding the four virus strains and notes a chemical trial conducted by a city-based private university.

Future developments include the implementation of the vaccine for the eligible age group and the ongoing management of dengue virus strain immunity.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 43d ago.

Who reported it (8)

Momentum

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Topics

Takeda Qdenga India DCGI Dengue

From around our network

Related trends

Open prediction lab

Can you beat the machine?

Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.

Make a prediction →